{
    "title": "R42960",
    "content": "The Hatch-Waxman Act of 1984 reformed patent and food and drug laws to balance innovation and competition in the pharmaceutical industry. Congressional attention has focused on pharmaceutical patent litigation settlements, as brand-name companies must litigate in federal courts to enforce their patents against generic competitors. The settlement of pharmaceutical patent litigation involves brand-name companies enforcing their patents against generic competitors through federal court litigation. Settlements may include agreements for the generic firm to not challenge the patents or sell a generic version in exchange for cash from the brand-name company. Reverse payment settlements in pharmaceutical patent litigation involve agreements where the generic firm receives cash payments from the brand-name company in exchange for not challenging patents or selling generic versions of the drug. These settlements are also known as \"pay-for-delay\" agreements and have varying opinions among commentators. Some observers term reverse payment settlements in pharmaceutical patent litigation as \"pay-for-delay\" agreements. Views on these settlements vary, with some attributing them to specialized patent litigation procedures while others see them as anti-competitive. Congress requires notification of these settlements to antitrust authorities since 2003, but has not set substantive standards for assessing their validity under antitrust law. Judicial application of general antitrust principles determines the validity of these agreements, leading to varying outcomes in different cases. The U.S. Supreme Court decision in Federal Trade Commission v. Actavis, Inc. on June 17, 2013, established that reverse payment settlements in pharmaceutical patent litigation should be evaluated under the \"rule of reason\" approach. This ruling clarified the legality of such agreements, which were previously subject to varying interpretations by lower courts. Going forward, lower courts will need to apply the rule of reason to assess the validity of reverse payment settlements. The U.S. Supreme Court decision in Federal Trade Commission v. Actavis, Inc. established that reverse payment settlements in pharmaceutical patent litigation should be evaluated under the \"rule of reason\" approach. Legislation before the 113th Congress also addresses reverse payment settlements, with proposed bills aiming to create a rebuttable presumption of illegality and introduce reforms to reduce incentives for generic firms to settle with brand-name companies. This report analyzes innovation and competition policy issues associated with pharmaceutical patent litigation settlements. The FAIR Generics Act (S. 504) aims to reduce incentives for generic firms to settle with brand-name companies in pharmaceutical patent litigation. The report discusses reverse payment settlements and their status under antitrust laws, along with congressional issues and possible alternatives. Inventors must submit patent applications to the USPTO for patent protection. Inventors must submit patent applications to the USPTO for patent protection. USPTO examiners assess applications for patent eligibility based on novelty and nonobviousness criteria. Applicants must provide a detailed description of their invention and draft claims that define the subject matter of their invention. When submitting a patent application, inventors must define their invention and claim its novelty and nonobviousness. The USPTO examiner evaluates if the invention meets patentability standards, including being novel and not obvious based on prior art. If granted, the patent owners have exclusive rights to their invention. The USPTO evaluates patent applications for novelty and nonobviousness based on prior art. If granted, patent owners have exclusive rights to their invention for twenty years. This allows inventors to profit from their discovery by charging higher prices and limiting competition. The grant of a patent allows inventors to have periods of exclusivity to practice their inventions or license others to do so. Patent owners must monitor competitors and may need to litigate to enforce their rights. While a patent provides proprietary interest, FDA permission is required to distribute pharmaceutical products. Owners seeking to enforce intellectual property rights often resort to litigation in federal district courts. While a patent grants proprietary rights to a pharmaceutical product, distribution requires FDA approval. Developers must prove safety and efficacy through preclinical and clinical investigations for FDA marketing approval. The FDA evaluates data in a New Drug Application to decide on approval. Before the Hatch-Waxman Act, there were no specific provisions for generic versions of previously approved drugs. The FDA evaluates test data in a New Drug Application (NDA) for marketing approval. Before the Hatch-Waxman Act, generic drug manufacturers had to file their own NDA. Some could submit a \"paper NDA\" based on published literature, but not all drugs had this option. FDA sometimes requested additional studies for safety and efficacy concerns post-approval. Some generic manufacturers faced challenges proving the safety and efficacy of their drugs, even though they were chemically identical to approved pharmaceuticals. Critics argued that the approval process for generic drugs was costly and time-consuming, discouraging manufacturers from introducing generic equivalents for expired patents. The approval process for generic drugs was seen as costly and time-consuming, leading to a lack of generic equivalents for expired patents. Congress enacted the Hatch-Waxman Act to create an expedited pathway for generic drug approval called an Abbreviated New Drug Application (ANDA), allowing bioequivalence without extensive clinical data. The Abbreviated New Drug Application (ANDA) allows generic drugs to obtain marketing approval by demonstrating bioequivalence to pioneer drugs without extensive clinical data. It helps generic manufacturers avoid costs and delays associated with filing a full NDA and allows them to enter the market when relevant patents expire. Congress also provided patent proprietors with a five-year extension period to compensate for lost patent term while awaiting FDA approval. The patent term extension allows brand-name firms to compensate for lost time while awaiting FDA approval for their drugs. The extension period is capped at five years, resulting in a total effective patent term of up to 14 years. This extension is intended to reward brand-name firms for the pre-clinical and clinical data they have generated, which is often costly. The Hatch-Waxman Act established procedures for resolving patent disputes in generic drug applications, compensating brand-name firms for their pre-clinical and clinical data. The Hatch-Waxman Act created procedures for resolving patent disputes in generic drug applications. NDA applicants must file a list of patents they believe would be infringed by generic drugs. The FDA publishes these patents in the \"Orange Book.\" Generic drug manufacturers must certify their views on Orange Book-listed patents when applying for approval. Generic drug manufacturers engage in a certification procedure for Orange Book-listed patents when applying for approval. Certifications include stating views on patents, expiration status, agreement not to market, or patent invalidity. Certifications are termed paragraph I, II, III, and IV. Approval for ANDA certified under paragraphs I or II is immediate, while paragraph III requires further steps. An ANDA can be certified under paragraphs I, II, III, or IV. Approval for paragraphs I or II is immediate, while paragraph III requires waiting for the brand-name drug's patent to expire. Filing with a paragraph IV certification can lead to patent infringement litigation under the Hatch-Waxman Act. The Hatch-Waxman Act incentivizes challenges to pharmaceutical patents by granting a 180-day exclusivity period to the first generic applicant filing a paragraph IV certification. This provision aims to stimulate competition and potentially higher profits for the initial ANDA applicant. Following the Hatch-Waxman Act, the first generic applicant with a paragraph IV certification receives a 180-day exclusivity period. However, forfeiture events, such as failure to market promptly or obtain FDA approval in a timely manner, can lead to the loss of this exclusivity. The Medicare Prescription Drug, Improvement, and Modernization Act established forfeiture events for generic exclusivity, including failure to market promptly or obtain timely FDA approval. This was to prevent 'parking' of exclusivity periods. Filing a paragraph IV ANDA can lead to patent infringement suits by brand-name companies, potentially resulting in injunctions. Generic manufacturers may face patent infringement suits by brand-name companies for filing paragraph IV ANDAs, leading to potential injunctions preventing the marketing of the product. The courts may either grant an injunction if the NDA holder proves patent violation or rule in favor of the generic firm if the patents are deemed invalid or non-infringing. The courts may rule in favor of the independent generic firm if the proposed product does not infringe patents or if the patents are invalid. The generic firm can launch its product once the FDA approves its ANDA. Another resolution in pharmaceutical patent litigation is possible, where the NDA holder and generic applicant settle their dispute, with the generic firm agreeing not to challenge the patent. Reverse payment settlements in pharmaceutical patent litigation have raised concerns about their impact on social welfare. Critics argue that these agreements may lead to anticompetitive behavior, with firms colluding to restrict output and share patent-based profits. Reverse payment settlements in pharmaceutical patent litigation have sparked debate on their impact on social welfare. Critics argue that these agreements may lead to anticompetitive behavior, with firms colluding to restrict output and share profits. However, some believe that settlements promote judicial policy, allowing parties to avoid litigation expenses and achieve timely resolutions. Reverse payment settlements in pharmaceutical patent litigation are viewed favorably due to the judicial policy promoting settlement. Settlements help parties avoid litigation expenses, achieve timely resolutions, and exchange benefits and obligations. Judge Richard Posner explains that any settlement involves compensation to the defendant, leading to a prohibition on reverse payments potentially eliminating patent settlements. Reverse payment settlements in pharmaceutical patent litigation involve compensation to the defendant, potentially allowing for generic competition before the patent expires. These agreements may benefit consumers compared to a judgment upholding the patent. Dispute settlement procedures under the Hatch-Waxman Act may promote the use of reverse payment settlements. Reverse payment settlements in pharmaceutical patent litigation involve compensation to the defendant, potentially allowing for generic competition before the patent expires. Such agreements may benefit consumers compared to a judgment upholding the patent. The Hatch-Waxman Act's dispute settlement procedures may also promote the use of reverse payment settlements in pharmaceutical patent litigation. The Hatch-Waxman Act alters the balance of risks between patent holders and accused infringers, allowing generic manufacturers to challenge patents without facing significant financial risks. This can lead to settlements where the accused infringer compensates the patent holder to avoid potential injunctions and damages. The Hatch-Waxman Act allows generic firms to challenge patents with limited financial risk, leading to settlements where the generic firm's upside is exclusive sales while the patent holder faces the downside of losing the patent. Congressional action on pharmaceutical patent litigation settlements has been limited, with the 2003 Medicare Prescription Drug, Improvement, and Modernization Act mandating the DOJ and FTC to receive copies of certain patent settlement agreements. The 2003 Medicare Prescription Drug, Improvement, and Modernization Act mandated the DOJ and FTC to receive copies of certain patent settlement agreements in the pharmaceutical field. These agreements trigger the notification requirement if they relate to specific topics related to brand-name and generic drugs. The Medicare Prescription Drug Act mandated the DOJ and FTC to receive copies of patent settlement agreements in the pharmaceutical field. Agreements trigger notification if they relate to specific topics related to brand-name and generic drugs. Certain agreements are exempt from this filing requirement, such as purchase orders for raw materials or employment contracts. The FTC received 140 final resolutions of patent disputes in FY2012, with 40 settlements potentially involving brand and generic drugs. The FTC received 140 final resolutions of patent disputes in FY2012, with 40 settlements potentially involving pay-for-delay payments. The MMA imposed a filing obligation on certain patent settlements between pharmaceutical firms, but did not set substantive standards for their validity. Various government and private actors claimed that certain reverse payment settlements violated antitrust laws, leading to different court outcomes based on general antitrust principles. Various government and private actors asserted that certain reverse payment settlements violated antitrust laws, leading to different court outcomes based on general antitrust principles. The primary legal mechanism for addressing anti-competitive conduct, including reverse payment settlements, consists of the antitrust laws, which are comprised of various statutes prohibiting certain kinds of anticompetitive economic behavior. The antitrust laws, including the Sherman Act and Clayton Act, prohibit anti-competitive conduct such as reverse payment settlements. Section 1 of the Sherman Act declares any restraint of trade to be illegal, with courts using the \"rule of reason\" to determine if a practice is anti-competitive. The courts interpret the Sherman Act as applying only to unreasonable restraints of trade, determined under the \"rule of reason.\" This approach balances anticompetitive consequences against business justifications to assess reasonableness. Other restraints may be deemed unlawful per se. The rule of reason in antitrust law involves balancing anticompetitive consequences against business justifications to determine legality. Certain restraints are deemed per se illegal without elaborate inquiry, such as price fixing and market division. The per se illegality standard in antitrust law deems certain practices, like price fixing and market division, as illegal without detailed investigation. Courts may also use a \"quick look\" approach to assess antitrust violations, requiring defendants to justify their actions with pro-competitive reasons. Different approaches exist for evaluating reverse payment settlements in pharmaceutical patent litigation. In pharmaceutical patent litigation, reverse payment settlements are subject to antitrust scrutiny. The Sixth Circuit deemed a settlement agreement between Hoescht Marion Roussel Inc. and Andrx Pharmaceuticals as per se invalid due to being a horizontal agreement. The Court of Appeals held that a reverse payment settlement agreement between Hoescht Marion Roussel Inc. and Andrx Pharmaceuticals was per se invalid as a horizontal agreement, a restraint of trade involving businesses at the same level of competition. Despite early precedent, subsequent Courts of Appeals ruled that such settlements were permissible as long as they did not exceed the scope of the patent. The Eleventh and Federal Circuits ruled that reverse payment settlements are permissible as long as they do not exceed the scope of the patent. In Valley Drug Co. v. Geneva Pharmaceuticals, agreements between Abbott Laboratories and generic firms were challenged for horizontal market allocation. The Eleventh Circuit reversed the per se illegality ruling, remanding for scrutiny of any parts exceeding patent protections. The Court of Appeals reversed the per se illegality ruling on reverse payment settlements, remanding for scrutiny of agreements exceeding patent protections. The \"scope of the patent\" approach allows such settlements if they stay within patent boundaries and are not based on fraudulent claims. The Third Circuit rejected this approach, stating it restricts antitrust law application. The Court of Appeals for the Third Circuit rejected the scope of the patent test in K-Dur Antitrust Litigation, stating it improperly restricts antitrust law application and undermines congressional goals. The court emphasized that the presumption of validity for patents is procedural, not a substantive right for patent holders. The Court of Appeals for the Third Circuit rejected the scope of the patent test in K-Dur Antitrust Litigation, stating it improperly restricts antitrust law application and undermines congressional goals. The court emphasized that the presumption of validity for patents is procedural, not a substantive right for patent holders. The Court of Appeals also introduced a \"quick rule of reason\" test to assess anticompetitive reverse payments in settlement agreements. The Third Circuit rejected the scope of the patent test in antitrust law, adopting a \"quick rule of reason\" test for reverse payment settlements. The Supreme Court later ruled in Federal Trade Commission v. Actavis, Inc. that such settlements should be evaluated under the \"rule of reason\" approach, without being presumptively illegal. Solvay Pharmaceuticals, the NDA holder of ANDROGEL\u00ae, faced challenges from generic firms Actavis and Paddock Laboratories. The Supreme Court ruled in Federal Trade Commission v. Actavis, Inc. that reverse payment settlements should be evaluated under the \"rule of reason\" approach, not presumptively illegal. Solvay Pharmaceuticals settled with generic firms Actavis and Paddock Laboratories, paying them to delay launching their generic products. The FTC charged the parties with unlawfully sharing in Solvay's monopoly profits and abandoning their patent challenges. The FTC charged Solvay Pharmaceuticals and generic firms Actavis and Paddock Laboratories with violating antitrust laws by agreeing to delay launching generic products in exchange for sharing in Solvay's profits. The Eleventh Circuit Court affirmed the District Court's rejection of the FTC's claims, citing the \"scope of the patent\" standard. The Supreme Court later reversed this decision in a 5-3 ruling. The Court of Appeals explained that a reverse payment settlement is immune from antitrust attack if its anticompetitive effects fall within the exclusionary potential of the patent. The Supreme Court reversed the Eleventh Circuit's judgment in a 5-3 ruling, stating that the anticompetitive effects of the agreement between Solvay and the generic firms did not immunize it from antitrust scrutiny. Justice Breyer emphasized that while a valid patent holder may be exempt from antitrust liability, litigation under the Hatch-Waxman Act involves assertions of patent invalidity or noninfringement. The Supreme Court ruled that anticompetitive effects of agreements between patent holders and generic firms do not immunize them from antitrust scrutiny. Justice Breyer emphasized that litigation under the Hatch-Waxman Act involves patent validity or noninfringement assertions, which can impact competition. The Court stated that antitrust legality should be measured against procompetitive policies, not just patent law. The Supreme Court ruled that anticompetitive effects of agreements between patent holders and generic firms do not immunize them from antitrust scrutiny. Justice Breyer emphasized that antitrust legality should be measured against procompetitive policies, not just patent law. The Court considered traditional antitrust factors in determining the antitrust question related to patent-related settlements. The Supreme Court ruled that agreements between patent holders and generic firms are not immune from antitrust scrutiny. Justice Breyer emphasized that antitrust legality should be based on procompetitive policies, not just patent law. The Court considered traditional antitrust factors in assessing the antitrust implications of patent-related settlements. Justice Breyer argued against the Eleventh Circuit's near-automatic antitrust immunity for reverse payment settlements. He highlighted the risks of anticompetitive effects, inability to justify large payments, market power from patents, and the possibility of settling disputes without such payments. These factors outweighed the strong consideration for settlements in the Court's decision. In contrast to the Eleventh Circuit's near-automatic antitrust immunity for reverse payment settlements, Justice Breyer emphasized the risks of anticompetitive effects, inability to justify large payments, and the potential for settling disputes without such payments. He rejected the idea of presumptively unlawful reverse payment settlements and emphasized the need to consider various factors to determine their anticompetitive effects. The Court concluded that the FTC must establish antitrust liability using the traditional rule of reason analysis for reverse payment settlements, rejecting the near-automatic antitrust immunity approach. Chief Justice Roberts, along with Justices Scalia and Thomas, dissented, suggesting that antitrust law is violated only in specific circumstances related to the scope of the patent or fraud. The Supreme Court ruled that the FTC must prove antitrust liability using the rule of reason analysis for reverse payment settlements. Chief Justice Roberts, Justices Scalia, and Thomas dissented, arguing that antitrust law is violated only in specific patent-related circumstances. They expressed concerns about discouraging generic firms from challenging patents and weakening patent protection for innovators. The Actavis decision does not eliminate the ability to settle pharmaceutical patent litigation under the Hatch-Waxman Act, but parties must carefully structure and explain their agreements. The Supreme Court's Actavis decision upholds the rule of reason analysis for reverse payment settlements in pharmaceutical patent cases. Parties must carefully structure their agreements to avoid antitrust liability. Justice Breyer believes antitrust cases won't always involve detailed patent examination, while Chief Justice Roberts is concerned about the complexity and cost of resolving patent issues in antitrust disputes. The Chief Justice expressed concern that patent validity and infringement are central to antitrust disputes, suggesting Congress consider further judicial developments or regulation of pharmaceutical patent litigation settlements. The Chief Justice expressed concern about antitrust disputes related to patent validity and infringement, suggesting Congress consider further judicial developments or regulation of pharmaceutical patent litigation settlements. Two bills in the 113th Congress pertain to reverse payment settlements, including the Preserve Access to Affordable Generics Act, S. 27, which aims to regulate such settlements by declaring certain agreements as acts of unfair competition. The Fair and Immediate Release of Generics Act, S. 504, aims to discourage reverse payment settlements by granting generic firms the right to share regulatory exclusivity if they win a patent challenge. This legislation would also require generic firms to comply with any deferred agreements. S. 504 proposes changes to the Hatch-Waxman Act to discourage reverse payment settlements. It grants generic firms the right to share regulatory exclusivity and obligates them to abide by deferred entry dates. Brand-name firms must decide on patent enforcement within 45 days of a challenge by a generic firm. Pharmaceutical patent litigation settlements are crucial for public health. The Hatch-Waxman Act requires brand-name firms to respond to a patent challenge by a generic firm within 45 days. Pharmaceutical patent litigation settlements are important for public health as they balance the need for innovation with increased access to medications."
}